Incannex Healthcare Q3 EPS $(0.35) Beats $(0.79) Estimate
Incannex Healthcare Officially Commences DReAMzz Clinical Study for IHL-42X in Obstructive Sleep Apnea
Incannex Healthcare Wins MedTech Breakthrough Award for IHL-42X, Underscoring Leadership in Next-Generation Drug Development
Incannex Healthcare PSX-001 Program Aligns with White House Executive Order Accelerating Access to Psychedelic Treatments for Serious Mental Illness
Incannex Healthcare Says It Believes PSX-001 Development Program Aligns With Goals Outlined In Executive Order, Accelerating Medical Treatments For Serious Mental Illness
Incannex Reactivates Share Repurchase Program, Underscoring Confidence in Valuation and Strategic Position
Incannex Healthcare Announces Partnership with the AASM Foundation in Support of Sleep Apnea Research
Incannex Highlights Strong Balance Sheet with Approximately $75 Million in Cash and No Debt as Company Advances IHL-42X Development
Incannex Healthcare Holds ~$75M In Cash With No Debt
Incannex Regains Compliance with Nasdaq Minimum Bid Price Requirement
Incannex Healthcare Regains Nasdaq Compliance
Incannex Healthcare Inc. Announces Pricing of $10 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Incannex Strengthens Clinical Development Pathway for IHL-42X Following Positive Phase 2 Outcomes
Incannex Stock Slides As $10 Million Capital Raise Funds Next Study For Sleep Apnea Treatment
Incannex Healthcare shares are trading lower after the company announced it company announced the commencement of a $10 million offering of 2 million shares at $5.00 per share.
Incannex Healthcare Announces Enhanced Clinical Development Strategy For IHL-42X To Treat Obstructive Sleep Apnea
Incannex Healthcare Inc. (IXHL) Implements 1-for-30 Reverse Split Effective February 26
Trading Halt: Halt status updated at 8:55:00 AM ET: Quotation Resumption: News and Resumption Times
Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.